- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
TRIM68 Antibody (C-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP17177b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP17177b-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
TRIM68 Antibody (C-term) - Product info | |
| Application | WB
|
| Primary Accession | Q6AZZ1 |
| Other Accession | NP_060543.5 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 56259 Da |
TRIM68 Antibody (C-term) - Additional info | |
| Gene ID 55128 | |
| Other Names TRIM68; GC109; RNF137; SS56; E3 ubiquitin-protein ligase TRIM68; RING finger protein 137; SSA protein SS-56; Tripartite motif-containing protein 68 | |
| Target/Specificity This TRIM68 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 381-411 amino acids from the C-terminal region of human TRIM68. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions TRIM68 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
TRIM68 Antibody (C-term) - Protein Information | |
| Name TRIM68 | |
| Synonyms GC109, RNF137, SS56 | |
| Function Functions as an ubiquitin E3 ligase. Acts as a coactivator of androgen receptor (AR) depending on its ubiquitin ligase activity | |
| Cellular Location Cytoplasm, perinuclear region. Nucleus. Note=Colocalized with AR in nucleus | |
| Tissue Location Widely expressed. Expressed at high levels in prostate cancer cell lines. Up-regulation could be restricted to androgen-dependent cells | |
TRIM68 Antibody (C-term) - Related products
AP17177b: TRIM68 Antibody (C-term)
TRIM68 Antibody (C-term) - Application data
-
TRIM68 Antibody (C-term) (Cat. #AP17177b) western blot analysis in NCI-H460 cell line lysates (35ug/lane).This demonstrates the TRIM68 antibody detected the TRIM68 protein (arrow).
TRIM68 Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The protein encoded by this gene contains a RING finger domain, a motif present in a variety of functionally distinct proteins and known to be involved in protein-protein and protein-DNA interactions. This gene is expressed in many cancer cell lines. Its expression in normal tissues, however, was found to be restricted to prostate. This gene was also found to be differentially expressed in androgen-dependent versus androgen-independent prostate cancer cells.
REFERENCES
Malhotra, A., et al. Diabetes Metab. Res. Rev. 25(8):740-747(2009) Miyajima, N., et al. Cancer Res. 68(9):3486-3494(2008) Chang, G.T., et al. Eur. J. Cancer 37(16):2129-2134(2001) Billaut-Mulot, O., et al. J. Clin. Invest. 108(6):861-869(2001) Simpson, J.C., et al. EMBO Rep. 1(3):287-292(2000)